<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2025-3-103-108</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1781</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group></article-categories><title-group><article-title>Трудности диагностики и лечения склеродермического почечного криза (клиническое наблюдение)</article-title><trans-title-group xml:lang="en"><trans-title>Challenges in diagnosis and treatment of scleroderma renal crisis (clinical case report)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-2145-5330</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мишина</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Mishina</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow, 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3248-6426</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ананьева</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Mishina</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лидия Петровна Ананьева </p><p>115522, Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>Lidiya Petrovna Ananyeva </p><p>34A, Kashirskoye Shosse, Moscow, 115522 </p></bio><email xlink:type="simple">lpana@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6629-3374</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евсикова</surname><given-names>М. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Evsikova</surname><given-names>M. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow, 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3650-7658</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Koneva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow, 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2025</year></pub-date><volume>19</volume><issue>3</issue><fpage>103</fpage><lpage>108</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мишина Е.М., Ананьева Л.П., Евсикова М.Д., Конева О.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Мишина Е.М., Ананьева Л.П., Евсикова М.Д., Конева О.А.</copyright-holder><copyright-holder xml:lang="en">Mishina E.M., Mishina E.M., Evsikova M.D., Koneva O.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1781">https://mrj.ima-press.net/mrj/article/view/1781</self-uri><abstract><p>Рассмотрены патогенез и подходы к диагностике склеродермического почечного криза – СПК (острой «склеродермической» почки) – тяжелого проявления системной склеродермии (ССД), отличающегося высокой смертностью. В связи с недостаточным пониманием патогенетических механизмов лечение СПК не разработано.Описано развитие острого СПК у пациентки 43 лет, которая в течение 1,5 лет страдала диффузной формой ССД с быстропрогрессирующим течением и вовлечением внутренних органов на фоне высокой иммунологической активности. Данный случай интересен тем, что почечный криз развился во время госпитализации и был прослежен с первых дней на фоне хорошо документированной терапии. В лечении пациентки было использовано несколько препаратов с разным механизмом действия, включая ритуксимаб, микофенолата мофетил, ингибитор фосфодиэстеразы 5 (силденафил), а также курсы простаноидов. При этом доза глюкокортикоидов было низкой (метипред – 8 мг/сут). Достигнуто полное купирование СПК с восстановлением почечной функции.</p></abstract><trans-abstract xml:lang="en"><p>The pathogenesis and diagnostic approaches to scleroderma renal crisis (SRC) – an acute “scleroderma kidney” – a severe and life-threatening complication of systemic sclerosis (SSc) characterized by high mortality, are discussed. Due to limited understanding of the underlying pathogenic mechanisms, a standardized treatment for SRC has not been developed.We describe the development of acute SRC in a 43-year-old female patient with diffuse form of SSc of 1.5 years’ duration, rapidly progressive disease course, and internal organ involvement associated with high immunological activity. This case is notable in that the renal crisis developed during hospitalization and was observed from the earliest days under well-documented therapy. The treatment involved the use of several agents with different mechanisms of action, including rituximab, mycophenolate mofetil, a phosphodiesterase-5 inhibitor (sildenafil), and courses of prostanoids. The glucocorticoid dose remained low (methylprednisolone 8 mg/day). Complete resolution of SRC was achieved with restoration of renal function.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>склеродермический почечный криз</kwd><kwd>системная склеродермия</kwd><kwd>ритуксимаб</kwd><kwd>простаноиды</kwd></kwd-group><kwd-group xml:lang="en"><kwd>scleroderma renal crisis</kwd><kwd>systemic sclerosis</kwd><kwd>rituximab</kwd><kwd>prostanoids</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Volkmann ER, Andreasson K, Smith V. Systemic sclerosis. Lancet. 2023 Jan 28;401(10373):304-318. doi:10.1016/S0140-6736(22)01692-0. Epub 2022 Nov 25.</mixed-citation><mixed-citation xml:lang="en">Volkmann ER, Andreasson K, Smith V. Systemic sclerosis. Lancet. 2023 Jan 28;401(10373):304-318. doi:10.1016/S0140-6736(22)01692-0. Epub 2022 Nov 25.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022 Mar; 38(3):187-195. doi: 10.1002/kjm2.12505. Epub 2022 Mar 2.</mixed-citation><mixed-citation xml:lang="en">Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022 Mar; 38(3):187-195. doi: 10.1002/kjm2.12505. Epub 2022 Mar 2.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007 Jul;66(7):940-944. doi:10.1136/ard.2006.066068. Epub 2007 Feb 28.</mixed-citation><mixed-citation xml:lang="en">Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007 Jul;66(7):940-944. doi:10.1136/ard.2006.066068. Epub 2007 Feb 28.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Reggiani F, Moroni G, Ponticelli C. Kidney Involvement in Systemic Sclerosis. J Pers Med. 2022 Jul 10;12(7):1123. doi: 10.3390/jpm12071123.</mixed-citation><mixed-citation xml:lang="en">Reggiani F, Moroni G, Ponticelli C. Kidney Involvement in Systemic Sclerosis. J Pers Med. 2022 Jul 10;12(7):1123. doi: 10.3390/jpm12071123.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Iliopoulos G, Daoussis D. Renal dysfunction in systemic sclerosis beyond scleroderma renal crisis. Rheumatol Int. 2021 Jul;41(7): 1203-1208. doi:10.1007/s00296-021-04855-x. Epub 2021 Apr 12.</mixed-citation><mixed-citation xml:lang="en">Iliopoulos G, Daoussis D. Renal dysfunction in systemic sclerosis beyond scleroderma renal crisis. Rheumatol Int. 2021 Jul;41(7): 1203-1208. doi:10.1007/s00296-021-04855-x. Epub 2021 Apr 12.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bussone G, Noël LH, Mouthon L. Manifestations rйnales de la sclйrodermie systemique. Nephrol Ther. 2011 Jun;7(3):192-9. doi: 10.1016/j.nephro.2011.03.006. Epub 2011 Apr 27</mixed-citation><mixed-citation xml:lang="en">Bussone G, Noël LH, Mouthon L. Manifestations rйnales de la sclйrodermie systemique. Nephrol Ther. 2011 Jun;7(3):192-9. doi: 10.1016/j.nephro.2011.03.006. Epub 2011 Apr 27</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chrabaszcz M, Małyszko J, Sikora M, et al. Renal Involvement in Systemic Sclerosis: An Update. Kidney Blood Press Res. 2020;45(4): 532-548. doi:10.1159/000507886. Epub 2020 Jun 10.</mixed-citation><mixed-citation xml:lang="en">Chrabaszcz M, Małyszko J, Sikora M, et al. Renal Involvement in Systemic Sclerosis: An Update. Kidney Blood Press Res. 2020;45(4): 532-548. doi:10.1159/000507886. Epub 2020 Jun 10.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998 Sep;41(9):1613-1619. doi: 10.1002/1529-0131(199809)41:9&lt;1613::AIDART11&gt;3.0.CO;2-O.</mixed-citation><mixed-citation xml:lang="en">Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998 Sep;41(9):1613-1619. doi: 10.1002/1529-0131(199809)41:9&lt;1613::AIDART11&gt;3.0.CO;2-O.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Woodworth TG, Suliman YA, Li W, et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016 Nov;12(11):678-691. doi: 10.1038/nrneph.2016.124. Epub 2016 Sep 19.</mixed-citation><mixed-citation xml:lang="en">Woodworth TG, Suliman YA, Li W, et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016 Nov;12(11):678-691. doi: 10.1038/nrneph.2016.124. Epub 2016 Sep 19.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Iudici M. What should clinicians know about the use of glucocorticoids in systemic sclerosis? Mod Rheumatol. 2017 Nov;27(6): 919-923. doi:10.1080/14397595.2016.1270796. Epub 2017 Jan 6.</mixed-citation><mixed-citation xml:lang="en">Iudici M. What should clinicians know about the use of glucocorticoids in systemic sclerosis? Mod Rheumatol. 2017 Nov;27(6): 919-923. doi:10.1080/14397595.2016.1270796. Epub 2017 Jan 6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hudson M, Ghossein C, Steen V. Scleroderma renal crisis. Presse Med. 2021 Apr;50(1): 104063. doi:10.1016/j.lpm.2021.104063. Epub 2021 Feb 3.</mixed-citation><mixed-citation xml:lang="en">Hudson M, Ghossein C, Steen V. Scleroderma renal crisis. Presse Med. 2021 Apr;50(1): 104063. doi:10.1016/j.lpm.2021.104063. Epub 2021 Feb 3.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mouthon L, Bussone G, Berezne A, et al. Scleroderma renal crisis. J Rheumatol. 2014 Jun;41(6):1040-8. doi: 10.3899/jrheum.131210. Epub 2014 May 15.</mixed-citation><mixed-citation xml:lang="en">Mouthon L, Bussone G, Berezne A, et al. Scleroderma renal crisis. J Rheumatol. 2014 Jun;41(6):1040-8. doi: 10.3899/jrheum.131210. Epub 2014 May 15.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018 Feb 7;13(2): 300-317. doi: 10.2215/CJN.00620117. Epub 2017 Oct 17.</mixed-citation><mixed-citation xml:lang="en">Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018 Feb 7;13(2): 300-317. doi: 10.2215/CJN.00620117. Epub 2017 Oct 17.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cole A, Ong VH, Denton CP. Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis. Clin Rev Allergy Immunol. 2023 Jun;64(3):378-391. doi: 10.1007/s12016-022-08945-x. Epub 2022 Jun 1.</mixed-citation><mixed-citation xml:lang="en">Cole A, Ong VH, Denton CP. Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis. Clin Rev Allergy Immunol. 2023 Jun;64(3):378-391. doi: 10.1007/s12016-022-08945-x. Epub 2022 Jun 1.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Foocharoen C, Tonsawan P Pongkulkiat P, et al. Management review of scleroderma renal crisis: An update with practical pointers. Mod Rheumatol. 2023 Jan 3;33(1):12-20. doi: 10.1093/mr/roac028.</mixed-citation><mixed-citation xml:lang="en">Foocharoen C, Tonsawan P Pongkulkiat P, et al. Management review of scleroderma renal crisis: An update with practical pointers. Mod Rheumatol. 2023 Jan 3;33(1):12-20. doi: 10.1093/mr/roac028.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H, Lefebvre F, Hoa S, Hudson M. Mortality and morbidity in scleroderma renal crisis: A systematic literature review. J Scleroderma Relat Disord. 2021 Feb;6(1):21-36. doi:10.1177/2397198320920422. Epub 2020 Jun 1.</mixed-citation><mixed-citation xml:lang="en">Kim H, Lefebvre F, Hoa S, Hudson M. Mortality and morbidity in scleroderma renal crisis: A systematic literature review. J Scleroderma Relat Disord. 2021 Feb;6(1):21-36. doi:10.1177/2397198320920422. Epub 2020 Jun 1.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025 Jan;84(1):29-40. doi: 10.1136/ard-2024-226430. Epub 2025 Jan 2.</mixed-citation><mixed-citation xml:lang="en">Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025 Jan;84(1):29-40. doi: 10.1136/ard-2024-226430. Epub 2025 Jan 2.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lynch BM, Stern EP, Ong V, et al. UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):106-109. Epub 2016 Sep 29.</mixed-citation><mixed-citation xml:lang="en">Lynch BM, Stern EP, Ong V, et al. UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):106-109. Epub 2016 Sep 29.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">de Zubiria-Maria A, Florez-Suarez JB, Mendez-Patarroyo P, et al. Pharmacological treatment of scleroderma renal crisis: a systematic literature review. Rev Colomb Reumatol. 2020;27:111–125. doi: 10.1016/j.rcreue.2020.01.003.</mixed-citation><mixed-citation xml:lang="en">de Zubiria-Maria A, Florez-Suarez JB, Mendez-Patarroyo P, et al. Pharmacological treatment of scleroderma renal crisis: a systematic literature review. Rev Colomb Reumatol. 2020;27:111–125. doi: 10.1016/j.rcreue.2020.01.003.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Uriarte MH, Larrarte C, Rey LB. Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab. Case Rep Nephrol. 2018 Oct 23;2018:6051083. doi:10.1155/2018/6051083.</mixed-citation><mixed-citation xml:lang="en">Uriarte MH, Larrarte C, Rey LB. Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab. Case Rep Nephrol. 2018 Oct 23;2018:6051083. doi:10.1155/2018/6051083.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ebata S, Yoshizaki-Ogawa A, Sato S, Yoshizaki A. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. J Clin Med. 2022 Aug 8;11(15):4631. doi: 10.3390/jcm11154631.</mixed-citation><mixed-citation xml:lang="en">Ebata S, Yoshizaki-Ogawa A, Sato S, Yoshizaki A. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. J Clin Med. 2022 Aug 8;11(15):4631. doi: 10.3390/jcm11154631.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Старовойтова МН, Десинова ОВ, Ананьева ЛП и др. Функция почек на фоне длительной терапии ритуксимабом у больных системной склеродермией. Современная ревматология. 2023;17(5):53-60. doi: 10.14412/1996-7012-2023-5-53-60.</mixed-citation><mixed-citation xml:lang="en">Starovoitova MN, Desinova OV, Ananyeva LP, et al. Renal function during long-term therapy with rituximab in patients with systemic sclerosis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023;17(5): 53-60. (In Russ.). doi: 10.14412/1996-7012-2023-5-53-60.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kong W, Wang Y, Wang H, et al. Systemic sclerosis complicated with renal thrombotic microangiopathy: a case report and literature review. BMC Nephrol. 2022 Jan 10;23(1):22. doi:10.1186/s12882-021-02639-w.</mixed-citation><mixed-citation xml:lang="en">Kong W, Wang Y, Wang H, et al. Systemic sclerosis complicated with renal thrombotic microangiopathy: a case report and literature review. BMC Nephrol. 2022 Jan 10;23(1):22. doi:10.1186/s12882-021-02639-w.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Innami K, Mukai T, Kodama S, Morita Y. Successful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisis. BMJ Case Rep. 2017 Sep 23;2017:bcr2017221205. doi:10.1136/bcr-2017-221205.</mixed-citation><mixed-citation xml:lang="en">Innami K, Mukai T, Kodama S, Morita Y. Successful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisis. BMJ Case Rep. 2017 Sep 23;2017:bcr2017221205. doi:10.1136/bcr-2017-221205.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
